An Update on Animal Models of Autoimmune Hepatitis: Are we There Yet?
An Update on Animal Models of Autoimmune Hepatitis: Are we There Yet?
复制标题
DOI：
10.2174/1381612821666150316121319
复制
发表时间：
2015-05
影响因子：
3.1
通讯作者：
U. Christen;E. Hintermann
中科院分区：
文献类型：
--
作者：
U. Christen;E. Hintermann
自身免疫性肝炎的特征是肝实质的进行性破坏和慢性纤维化。虽然这种自身免疫介导的疾病的主要靶点已经在二十多年前被确定，但目前自身免疫性肝炎的治疗仍然基于传统疗法，包括糖皮质激素治疗。造成这种僵局的一个原因是可靠的动物模型有限，这些模型反映了自身免疫性肝炎的临床特征，并允许识别驱动自身免疫性破坏的关键因素和评估创新疗法。然而，肝脏作为一个免疫特权器官，具有许多免疫抑制机制，阻碍了这种模型的发展。在这里，我们将回顾过去和现在的尝试，以建立一个一致的动物模型的自身免疫性肝炎。
Autoimmune hepatitis is characterized by a progressive destruction of the liver parenchyma and a chronic fibrosis. Although the major targets of this autoimmune-mediated disease have been identified more than two decades ago, the current treatment of autoimmune hepatitis is still based on traditional therapies including a glucocorticoid treatment. One reason for this impasse is the limited availability of reliable animal models that reflect the clinical features of autoimmune hepatitis and allow for the identification of critical factors driving the autoimmune destruction and the evaluation of innovative therapies. However, the status of the liver as an immune privileged organ harbouring many immunosuppressing mechanisms hampers the development of such models. Here we will review the past and present attempts to develop a consistent animal model for autoimmune hepatitis.